美国 · 财经报刊 · Barron's
Summit’s FDA Setback Is a Reality Check for Next-Gen Cancer Drugs
详细摘要
Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.barrons.com)